In vitro antifungal potency of the moronecidin-like peptide against Candida albicans, Candida glabrata, and Candida tropicalis

The aim of this study was to investigate the antifungal potency of the moronecidin-like peptide against , and To evaluate the antifungal effect of moronecidin-like peptide, the protocol presented in CLSI M27-A3 and CLSI M27-S4 was used and the minimum inhibitory concentration was determined. The minimum inhibitory effect of moronecidin-like peptide composition was 8 µg/ml for and and 32 µg/ml for . The MIC of nystatin was determined to be 1.25 µg/ml for and and 0.625 µg/ml for strains. The MFC composition of the moronecidin-like peptide was determined for and strains 8 µg/ml and for strain 64 µg/ml. The results of cytotoxicity and hemolysis of the moronecidin peptide test on macrophage showed that moronecidin peptide has no cytotoxicity and toxicity properties. According to the results of the present study, the moronecidin-like peptide could be a new strategy in the treatment of infections caused by strains. The discovery of the exact mechanism of which requires extensive clinical studies in this field.